GlassScriptPhysician profile
Aftab A Khan
NPI 1720073729
$7,199.46
in general payments reported to CMS, 2019-2025
42 companies · $849 in 2025
The $849 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $1,325 · 2021: $1,157 · 2022: $1,020 · 2023: $926 · 2024: $736 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $797.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $749.99 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $723.61 | 2020-2022 | |
| Allergan, INC. | $720.40 | 2019-2020 | |
| Abbvie INC. | $614.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $542.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $375.62 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $346.57 | 2019-2021 | |
| Lilly USA, LLC | $299.43 | 2019-2024 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.58 | 2019-2020 | |
| Novo Nordisk INC | $171.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $171.21 | 2019-2023 | Otezla, Repatha |
| Philips North America LLC | $169.97 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $159.00 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $128.65 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aftab Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.